目的探索β-细辛醚微乳利用鼻腔的鼻-脑通道实现鼻脑靶向给药的可行性。方法按0.42 mL/kg剂量鼻腔给予β-细辛醚微乳后用HPLC法测定药物在血浆中及脑中的浓度,并以iv自制微乳注射液为对照,以AUC脑/AUC血浆指标考察β-细辛醚微乳鼻腔给药的脑靶向性。结果β-细辛醚微乳鼻腔给药后得到的AUC脑/AUC血浆值均高于iv给药。结论鼻腔给予含药微乳系统后脑靶向性良好,有望成为治疗阿尔茨海默病的新型给药途径。 Objective To explore the feasibility of using β-asarone ether microemulsion to achieve nasal-brain targeting by nasal nasal-brain channel. Methods The concentration of β-asarone ether microemulsion was measured by intranasal administration of 0.42 mL / kg and HPLC was used to determine the concentration of drug in plasma and brain. The AUC brain / AUC plasma indexes were determined by iv microemulsion injection Brain targeting of β-asarone microemulsion for nasal administration. Results AUC brain / AUC plasma values ​​obtained after nasal administration of β-asarone microemulsion were higher than those of iv administration. CONCLUSIONS: The nasal cavity containing drug-loaded microemulsion has good brain targeting and is expected to become a new route of treatment for Alzheimer’s disease.